{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:48:06Z","timestamp":1759160886786,"version":"3.43.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,13]]},"DOI":"10.7759\/cureus.89996","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:22:48Z","timestamp":1755098568000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Cardiotoxicity Induced by 5-Fluorouracil Successfully Treated With Levosimendan: A Case Report"],"prefix":"10.7759","author":[{"given":"Carlos","family":"Wu-Ching","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Z\u00fa\u00f1iga-Orlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Salas-Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Lostalo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeaustin","family":"Mora-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Cruz-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8468","article-title":"Fluoropyrimidine\u2011induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)","volume":"49","author":"Lombardi P","year":"2023","unstructured":"Lombardi P, Aimar G, Peraldo-Neia C, et al.. Fluoropyrimidine\u2011induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT). Oncol Rep. 2023, 49:31. 10.3892\/or.2022.8468","journal-title":"Oncol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk M","year":"2021","unstructured":"Jurczyk M, Kr\u00f3l M, Midro A, Kurnik-\u0141ucka M, Poniatowski A, Gil K. Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management. J Clin Med. 2021, 10:4426. 10.3390\/jcm10194426","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2017.06.003","article-title":"Effective use of levosimendan in anthracycline-induced cardiomyopathy: a case report","volume":"46","author":"Miaris N","year":"2017","unstructured":"Miaris N, Zezas S, Sgouros J, et al.. Effective use of levosimendan in anthracycline-induced cardiomyopathy: a case report. Heart Lung. 2017, 46:382-6. 10.1016\/j.hrtlng.2017.06.003","journal-title":"Heart Lung"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara JD","year":"2018","unstructured":"Sara JD, Kaur J, Khodadadi R, et al.. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018, 10:1758835918780140. 10.1177\/1758835918780140","journal-title":"Ther Adv Med Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01441-2","article-title":"5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death","volume":"23","author":"More LA","year":"2021","unstructured":"More LA, Lane S, Asnani A. 5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death. Curr Cardiol Rep. 2021, 23:17. 10.1007\/s11886-021-01441-2","journal-title":"Curr Cardiol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-associated cardiotoxicity","volume":"37","author":"Kanduri J","year":"2019","unstructured":"Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-associated cardiotoxicity. Cardiol Clin. 2019, 37:399-405. 10.1016\/j.ccl.2019.07.004","journal-title":"Cardiol Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.991886","article-title":"Case report: acute toxic myocardial damage caused by 5-fluorouracil-from enigma to success","volume":"9","author":"Lasica R","year":"2022","unstructured":"Lasica R, Spasic J, Djukanovic L, Trifunovic-Zamaklar D, Orlic D, Nedeljkovic-Arsenovic O, Asanin M. Case report: acute toxic myocardial damage caused by 5-fluorouracil-from enigma to success. Front Cardiovasc Med. 2022, 9:991886. 10.3389\/fcvm.2022.991886","journal-title":"Front Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2022.153113","article-title":"ROS and iron homeostasis dependent ferroptosis play a vital role in 5-fluorouracil induced cardiotoxicity in vitro and in vivo","volume":"468","author":"Li D","year":"2022","unstructured":"Li D, Song C, Zhang J, Zhao X. ROS and iron homeostasis dependent ferroptosis play a vital role in 5-fluorouracil induced cardiotoxicity in vitro and in vivo. Toxicology. 2022, 468:153113. 10.1016\/j.tox.2022.153113","journal-title":"Toxicology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-022-23314-z","article-title":"Protective effect of quercetin against 5-fluorouracil-induced cardiac impairments through activating Nrf2 and inhibiting NF-\u03baB and caspase-3 activities","volume":"30","author":"Lokman MS","year":"2023","unstructured":"Lokman MS, Althagafi HA, Alharthi F, et al.. Protective effect of quercetin against 5-fluorouracil-induced cardiac impairments through activating Nrf2 and inhibiting NF-\u03baB and caspase-3 activities. Environ Sci Pollut Res Int. 2023, 30:17657-69. 10.1007\/s11356-022-23314-z","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.07.202","article-title":"Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper","volume":"222","author":"Farmakis D","year":"2016","unstructured":"Farmakis D, Alvarez J, Gal TB, et al.. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016, 222:303-12. 10.1016\/j.ijcard.2016.07.202","journal-title":"Int J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2017.07.001","article-title":"Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis","volume":"184","author":"Qiu J","year":"2017","unstructured":"Qiu J, Jia L, Hao Y, et al.. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017, 184:30-6. 10.1016\/j.lfs.2017.07.001","journal-title":"Life Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216408","article-title":"Use of levosimendan in patients with advanced heart failure: an update","volume":"11","author":"Masarone D","year":"2022","unstructured":"Masarone D, Kittleson MM, Pollesello P, et al.. Use of levosimendan in patients with advanced heart failure: an update. J Clin Med. 2022, 11:6408. 10.3390\/jcm11216408","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.05.078","article-title":"Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes","volume":"667","author":"Markou T","year":"2011","unstructured":"Markou T, Makridou Z, Galatou E, Lazou A. Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes. Eur J Pharmacol. 2011, 667:298-305. 10.1016\/j.ejphar.2011.05.078","journal-title":"Eur J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz163","article-title":"Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy","volume":"116","author":"Efentakis P","year":"2020","unstructured":"Efentakis P, Varela A, Chavdoula E, et al.. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy. Cardiovasc Res. 2020, 116:576-91. 10.1093\/cvr\/cvz163","journal-title":"Cardiovasc Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.07.051","article-title":"Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity","volume":"118","author":"Garcia JA","year":"2007","unstructured":"Garcia JA, Simvoulidis LF, Salluh JI, et al.. Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity. Int J Cardiol. 2007, 118:406-7. 10.1016\/j.ijcard.2006.07.051","journal-title":"Int J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0225","article-title":"Adjuvant treatment with 5-fluorouracil and oxaliplatin does not influence cardiac function, neurovascular control, and physical capacity in patients with colon cancer","volume":"25","author":"Groehs RV","year":"2020","unstructured":"Groehs RV, Negrao MV, Hajjar LA, et al.. Adjuvant treatment with 5-fluorouracil and oxaliplatin does not influence cardiac function, neurovascular control, and physical capacity in patients with colon cancer. Oncologist. 2020, 25:e1956-67. 10.1634\/theoncologist.2020-0225","journal-title":"Oncologist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia U","year":"2019","unstructured":"Campia U, Moslehi JJ, Amiri-Kordestani L, et al.. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation. 2019, 139:e579-602. 10.1161\/CIR.0000000000000641","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394089-acute-cardiotoxicity-induced-by-5-fluorouracil-successfully-treated-with-levosimendan-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:22:48Z","timestamp":1755098568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394089-acute-cardiotoxicity-induced-by-5-fluorouracil-successfully-treated-with-levosimendan-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.89996","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}